权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Innovative Approach to Geriatric Osteoporosis

老年骨质疏松症的创新方法

基本信息

批准号：
10624239
负责人：
SUSAN L GREENSPAN
金额：
$ 55.18万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10624239
关键词：
3-Dimensional Address Adverse event Age Anabolic Agents Bone Density Bone structure Calcium Cardiovascular system Characteristics Clinical Trials Cognitive Communities Consensus Consumption Dependence Disease Double-Blind Method Elderly Electronics Enrollment Event Exclusion FDA approved Face Forteo Fracture Frail Elderly Funding Goals Health Health care facility Hip Fractures Hip region structure Hospitalization Hypercalcemia Image Immobilization Impaired cognition Incidence Institutionalization International Investigation Lateral Location Long-Term Care Malnutrition Measurement Measures Monitor Notification Oral Osteoporosis Outcome Patients Personal Satisfaction Pharmaceutical Preparations Placebos Population Postmenopause Quality of life Randomized Regression Analysis Resources Risk Safety Self Administration Serious Adverse Event Site Spinal Fractures Structure System Techniques Testing Time Trabecular Bone Score United States National Institutes of Health Vertebral column Vitamin D Vitamin D Deficiency Woman Zoledronic Acid absorption bone bone loss bone turnover cardiovascular risk factor cohort comorbidity cost data mining efficacy evaluation efficacy testing fracture risk functional disability high risk population human old age (65+)improved inhibitor innovation mortality neglect novel osteoporosis with pathological fracture point of care prevent public health relevance responders and non-responders sedentary side effect skeletal spine bone structure subcutaneous substantia spongiosa

项目摘要

Although close to 85% of residents in long-term care facilities (LTC) have osteoporosis and the risk of osteoporotic fractures is nearly 10 times that of community dwelling elderly, few are treated and studies are scarce. The large pivotal osteoporosis trials in postmenopausal women exclude those who are sedentary, frail or functionally impaired even though this is the group at highest fracture risk. Before a fracture reduction study can be justified in this cohort, an investigation demonstrating efficacy and predictability is a necessary first step. We have previously demonstrated that zoledronic acid (ZOL) can maintain bone mineral density (BMD) and is safe in frail elderly. However a dual action anabolic antiresorptive agent has a distinct advantage to build bone rapidly. The newly approved once monthly dual action romosozumab (ROMO), provides significant improvements in BMD and fracture reduction in 1 year. If ROMO were given prior to a potent antiresorptive medication such as ZOL, this combination (rapid boost over a year with ROMO and maintain integrity 2nd year with ZOL) could provide a novel treatment paradigm in this high risk population. The concern for ROMO is the potential increase risk of cardiovascular events demonstrated in one pivotal study. Before a large fracture reduction trial can be justified in this frail population, a study demonstrating BMD efficacy and safety is imperative. We will test the hypotheses that in frail institutionalized women, one year of ROMO prior to one year of ZOL will 1) be more efficacious compared to one year of calcium plus vitamin D prior to a year of ZOL as demonstrated by improvements in conventional bone density measurements, 2) improve novel measures of bone trabecular microstructure and bone turnover markers, and 3) provide characteristics associated with responders and non-responders. To address these hypotheses, we propose to conduct a 2-year, randomized, double-blind controlled trial to test the efficacy and safety of ROMO (year 1) and ZOL (year 2) compared to calcium+vitamin D (year 1) and ZOL( year 2), in 200 institutionalized frail women age 65+ in LTC. Safety will be carefully monitored. Serious adverse events (SAE's) will be obtained by a novel electronic alert system that provides real time notifications including ROMO associated cardiovascular SAE's. This study includes innovative features: 1) focus on the neglected LTC population of frail residents in whom we have a track record of successful enrollment, 2) inclusion of a newly approved potent dual action agent feasible in LTC, 3) assessments of bone structure, 4) point of care vertebral fracture images, 5) mobile lab allowing onsite participation, and 6) electronic alerts for real time adverse events. Despite the call by national consensus groups for the past 2 decades to address osteoporosis in frail elderly, trials and treatments are sparse. This study will challenge the current paradigm of avoiding anti-osteoporosis therapy and provide an innovative approach for geriatric osteoporosis, and help target robust responders.

虽然近85%的长期护理机构（LTC）的居民患有骨质疏松症和风险